maprotiline has been researched along with naloxone in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Budziszewska, B; Grochmal, A; Przegaliński, E | 1 |
| Mendez, M; Miranda, HF; Pinardi, G; Sierralta, F | 1 |
| Gray, AM; Sewell, RD; Spencer, PS | 1 |
| Pettersen, VL; Raimundo, JM; Sudo, RT; Trachez, MM; Zapata-Sudo, G | 1 |
| Hajhashemi, V; Minaiyan, M; Movahedian, A; Sadeghi, H; Talebi, A | 1 |
1 review(s) available for maprotiline and naloxone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for maprotiline and naloxone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Oxaprotiline enantiomers stimulate ACTH and corticosterone secretion in the rat.
Topics: Adrenergic alpha-Antagonists; Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Benzylamines; Corticosterone; Dexamethasone; Diazepam; Dose-Response Relationship, Drug; Male; Maprotiline; Metergoline; Naloxone; Piperidines; Pyrimidines; Radioimmunoassay; Rats; Rats, Inbred Strains; Serotonin Antagonists; Stereoisomerism; Sulpiride; Sympathomimetics | 1991 |
Interaction of opioids with antidepressant-induced antinociception.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Clomipramine; Drug Combinations; Female; Imipramine; Male; Maprotiline; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Pain Measurement; Random Allocation; Selective Serotonin Reuptake Inhibitors; Zimeldine | 1995 |
The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds.
Topics: Abdominal Muscles; Acetic Acid; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Cyclobutanes; Dothiepin; Male; Maprotiline; Mice; Muscle Contraction; Naloxone; Naltrexone; Narcotic Antagonists; Neprilysin; Neurotransmitter Uptake Inhibitors; Opioid Peptides; Pain Measurement; Paroxetine; Protease Inhibitors; Receptors, Opioid; Selective Serotonin Reuptake Inhibitors; Thiorphan | 1998 |
The synergistic interaction between morphine and maprotiline after intrathecal injection in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amitriptyline; Analgesics, Opioid; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Citalopram; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Injections, Spinal; Male; Maprotiline; Morphine; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Pain Threshold; Rats; Rats, Wistar; Reaction Time; Selective Serotonin Reuptake Inhibitors; Time Factors; Yohimbine | 2009 |
Central and peripheral anti-inflammatory effects of maprotiline on carrageenan-induced paw edema in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Carrageenan; Edema; Hormone Antagonists; Indomethacin; Injections, Spinal; Male; Maprotiline; Mifepristone; Naloxone; Narcotic Antagonists; Prazosin; Propranolol; Rats; Rats, Wistar; Yohimbine | 2010 |